Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

This month’s spotlight into a disease or therapy area aligns with our rare disease focus month, as we look into how pharma can better support patients with Rett Syndrome. Our theme on pharmaphorum this month is on rare diseases and we’ve had a great response so far from rare disease patients, organisations and...

Articles

Rare diseases – where are the patients?

February is all about rare diseases and patients on pharmaphorum, and in this article, Neil Dickinson discusses the challenges for orphan drug marketers. Anyone involved in the marketing of orphan drugs for rare diseases must, at moments of weakness, surely have wished for...

Articles

Poor pharma corporate reputation – but what is the correct s...

Alexandra Wyke of PatientView highlights results of a recent report that provides an overview of pharma’s reputation with patient groups. A review of pharma reputation — as evaluated by 600 key patient groups worldwide —was published...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital